Pharmaids Pharmaceuticals (524572) Q3 24/25 earnings summary

Executive summary

• Board approved unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024.

• Re-appointment of Mr. Venu Madhava Kaparthy and Ms. Mini Manikantan as Whole-time Directors for three years, subject to shareholder approval.

• Approved sale of 3.45 acres of industrial land for Rs. 16.5 crore to Dr. S. N. Vinaya Babu, a related party, pending shareholder approval.

• Increase in authorized share capital from Rs. 45 crore to Rs. 101 crore, subject to shareholder approval.

• Approved issuance of a corporate guarantee up to Rs. 25 crore for subsidiary Adita Bio Sys Pvt Ltd.

Financial highlights

• Standalone revenue from operations for Q3 FY25: Rs. 120.79 lakh (vs. Rs. 2.08 lakh in Q3 FY24); nine months: Rs. 220.84 lakh (vs. Rs. 2.08 lakh in 9M FY24).

• Standalone net loss for Q3 FY25: Rs. 159.29 lakh (vs. Rs. 163.44 lakh loss in Q3 FY24); nine months: Rs. 422.28 lakh loss (vs. Rs. 343.91 lakh loss in 9M FY24).

• Consolidated revenue from operations for Q3 FY25: Rs. 470.93 lakh (vs. Rs. 2.08 lakh in Q3 FY24); nine months: Rs. 1,467.93 lakh (vs. Rs. 2.08 lakh in 9M FY24).

• Consolidated net loss for Q3 FY25: Rs. 301.45 lakh (vs. Rs. 163.44 lakh loss in Q3 FY24); nine months: Rs. 870.21 lakh loss (vs. Rs. 343.91 lakh loss in 9M FY24).

• Basic and diluted EPS (consolidated) for Q3 FY25: Rs. (0.55); nine months: Rs. (1.60).

Outlook and guidance

• Board is seeking shareholder approval for ESOP and ESPS schemes for employees of subsidiaries/associates.

• Strategic focus on realigning land assets and supporting subsidiary growth through guarantees.